GVB-2001-high dose

Small molecule

IIVIEW Therapeutics Inc.

GVB-2001-high dose is one of 27 small molecule programs targeting Glaucoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlaucomaActive, not recruiting

GlaucomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

182 competitors in Glaucoma

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

2 2

Viagra

VViatris Specialty LLC

Phase 3

1 3

Comparator: Pbo

Merck & Co.

Phase 3

1 4

Betoptic

Sanofi

Phase 3

1 5

Zioptan

MMeitheal

Phase 3

3 6

Gingko Biloba

Boehringer Ingelheim

Phase 3

1 7

Prostaglandin

LLaboratoires Thea

Phase 3

1 8

MMC in Trabeculectomy

PPro Top & Mediking Company Limited

Phase 3

2 9

Alphagan

AbbVie

Preclinical

2 10

Prostigmin

Merck & Co.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Glaucoma

NCT06921317

Clinical

Trials by Indication[1]

Glaucoma1 trial

GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma

Recruiting·IIVIEW Therapeutics Inc.·Phase 1/2·NCT06921317·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GVB-2001-high dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GVB-2001-high dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GVB-2001-high dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IVIEW Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IIVIEW Therapeutics Inc.

GVB-2001-high dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Glaucoma1 trial

References

Drug Info

Quick Facts

Related News